Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Voltaren Ophtha CD
- Development stage
- Unknown
- Lead developer
- Alcon
- Modality
- Small Molecules
- Administration
- Ophthalmic
01
Overview
Voltaren Ophtha CD is an ophthalmic formulation of diclofenac sodium 0.1% containing hydroxypropyl gamma-cyclodextrin (HPγ-CD) as an excipient to enhance solubility, stability, and ocular tolerability. Developed by Novartis (and its ophthalmic division Alcon), this non-steroidal anti-inflammatory drug (NSAID) works by inhibiting cyclooxygenase (COX) enzymes, thereby reducing prostaglandin synthesis and ocular inflammation. It is primarily indicated for the treatment of postoperative ocular inflammation and pain following cataract surgery, as well as the prevention of macular edema. In clinical trials, such as a Phase 4 study by UZ Leuven, Voltaren Ophtha CD has been evaluated alongside other preserved and preservative-free formulations to assess outcomes related to postoperative inflammation, iatrogenic dry eye disease, and macular edema.
- Brand names
- Voltaren Ophtha CD
- Other names
- diclofenac sodium 0.1% (hydroxypropyl gamma-cyclodextrin)
02
Targets
PTGS2 (Prostaglandin-Endoperoxide Synthase 2)PGHS-1 (Prostaglandin G/H Synthase 1)
Beyond the preview
Go deeper on Voltaren Ophtha CD.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Voltaren Ophtha CD.